NorthWest Biotherapeutics Inc (NWBO)

[sukus]

Thanks again Senti. The explanation makes a lot of sense to me especially when recurrent patients are being included too.

“And because our control arm was messed up by the cross over, comparing the treatment arm to a large group of comparable patients should suffice. Plus, the control arm in the DCVax trial will not go to waste as those patients' very valuable contributions will be compared to similar comparable controls from other recurrent GBM trials... and may result in a statistically significant comparison here as well, which would (upon an approval) make DCVax-L available to recurrent GBM patients. “